Colonic spasm can impair visualization of the dissection plane and limit scope maneuverability during colonic endoscopic submucosal dissection (ESD). The investigators framed submucosal lidocaine injection as a potential technique to reduce spasm and thereby facilitate ESD procedures.
The trial was a single-center, double-blind, randomized controlled study reported in Dig Endosc (2026 Sep). The study is indexed with PMID 42666074 and DOI 10.1111/den.70272. The research team included authors from the Department of Gastrointestinal Oncology, Osaka International Cancer Institute, and gastroenterology departments at Kyoto University Graduate School of Medicine and The University of Osaka Graduate School of Medicine.
The trial enrolled 110 patients who were scheduled to undergo colonic ESD. These patients were randomized to one of two groups: the lidocaine group or the control group. The abstract states random allocation and double-blinding but does not provide further details on inclusion/exclusion criteria, stratification, or concealment methods in the supplied text.
The abstract specifies the composition of the injected solutions but does not supply injection volumes, timing, number of injections, or technical details of how the submucosal injections were performed.
The predefined primary outcome reported in the abstract was procedure time. The abstract states that secondary outcomes were included, but the available text is truncated after naming secondary outcomes (the phrase ends at "Secondary outcomes included en bl"), so the full list of secondary endpoints is not visible in the provided source. The abstract does not show the statistical analysis plan, sample-size calculation, or thresholds for significance in the available excerpt.
The provided source contains the trial objective, design, participant number, interventions, and primary outcome, but the abstract is truncated and does not include numeric results, comparative analyses, effect sizes, p values, or authors’ conclusions. Specifically, the following are not reported in the supplied text:
Because these outcome data and analyses are missing from the supplied source text, they cannot be summarized or interpreted here.
The abstract indicates the study aimed to evaluate both efficacy and safety of submucosal lidocaine injection during colonic ESD, but no safety data, adverse-event rates, or tolerability findings are present in the provided excerpt. Details on monitoring, definitions of adverse events, or any reported complications are therefore not available in the supplied text.
From the text available in the supplied source, one can confirm the study question, randomized double-blind design, number of randomized participants (110), injected solutions, and the primary endpoint (procedure time). However, the abstract in the provided source is truncated and omits the trial’s outcome data, secondary outcomes, and safety results. Therefore, no conclusions about the efficacy or safety of submucosal lidocaine during colonic ESD can be drawn from this excerpt alone. For complete results and authors’ conclusions, consult the full text via the DOI or the PubMed Central record referenced on the PubMed page.